Apomorphine / Sildenafil / Tadalafil / Vardenafil Troches
Four-ingredient ED troche
From $69 · monthly supply
Rx · Prescription onlyInjected under the skin
Bremelanotide
On-demand desire boost.
Your plan
$159/mo, $954 billed once for 6 months/mo
$954 billed once for 6 months · unused months refunded on a medical stop
No membership fee · this is the full price · free shipping · avg 4-week supply
A licensed clinician on our care team reviews every request and prescribes only when it's clinically appropriate.
FDA status: Compounded medication, not FDA-approved.
Adults whose problem is desire, not blood flow.
It acts on desire in the brain. FDA-approved, as Vyleesi, for premenopausal women.
PT-141 (bremelanotide) is a melanocortin receptor agonist that increases sexual interest and arousal by activating receptors in the brain and body. It is FDA-approved as Vyleesi for women with hypoactive sexual desire disorder (HSDD). It is used off-label in men with low desire. Given as a subcutaneous injection 2–4 hours before sexual activity, PT-141 does not require daily dosing. Common side effect: nausea in the first hours (30–50% of users), often mild but sometimes requiring an antiemetic.
1 vial · lasts 4 weeks
2 mg/mL · 5 mL vial
Nausea and flushing are common with the first doses. No more than one dose in 24 hours.
PT-141, also called bremelanotide, acts on the desire pathway in the brain. Its one labeled use is for premenopausal women with low desire. The evidence in men is small and early.
Women's desire
0.30 and 0.42 points
Two identical 24-week trials in 1,267 premenopausal women with low desire, using bremelanotide 1.75 mg as needed against placebo. Desire rose 0.30 points more than placebo in one trial and 0.42 in the other. The effects are small.
Kingsberg et al., Obstetrics and Gynecology 2019Men, nasal
small early study
Diamond et al. tested intranasal PT-141 in healthy men and in men with mild-to-moderate erectile dysfunction, measuring erections with RigiScan. It was a small early safety, pharmacokinetic and pharmacodynamic study, not a phase 3 trial.
Diamond et al., International Journal of Impotence Research 2004Men, under the skin
no trial in men
We found no published phase 3 trial of PT-141 for erectile dysfunction in men. The product sold here is 0.2 mg per dose, a lower dose than the 1.75 mg studied in women, and it has no trial of its own.
PubMed search, bremelanotide and erectile dysfunction (2026)Trial figures are for bremelanotide 1.75 mg given under the skin in women. The PT-141 dispensed here is 0.2 mg per dose, a different dose with no trial of its own. Nausea, flushing, headache and vomiting were common in the women's trials.
FDA status: Compounded medication, not FDA-approved.
Tell your clinician about blood pressure medications, heart history, and any skin concerns.
Inject subcutaneously 2–4 hours before anticipated sexual activity. Effects peak around 1–2 hours after injection and last several hours. One dose per 24 hours maximum. If nausea occurs, taking an anti-nausea medication (like ondansetron) 30 minutes before PT-141 helps some people. Eat a light meal beforehand; a full meal can delay effects.
PT-141: sexual effects appear within 1–2 hours of injection, peak around 2 hours, last several hours. Results require dosing each time you want the effect.
PT-141: nausea is common (30–50%); anti-nausea medication beforehand helps. Rare: priapism in men (erection >4 hours)—seek emergency care. Stop immediately if any severe reaction occurs.
Tell your clinician about all medications, especially blood pressure drugs or cardiac medications. Some combinations need monitoring.
PT-141: as-needed indefinitely, or until your sexual health goals change. Annual check-ins with your clinician are recommended.
$159/mo · $954 billed once for 6 months
Four-ingredient ED troche
From $69 · monthly supply